Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Automated flows minimize manual tasks at McNeil

When the pharmaceutical company McNeil in Helsingborg was to upgrade its PAS-X, the overall MES system that controls and monitors large parts of their production, Prevas was engaged to develop Middleware that minimizes the risk of incorrect manual entries. “The goal was to link the automation systems with the MES,” says Mårten Åkesson, head of the automation group at McNeil. “Previously, it was the operators who were the connection between the two systems, which entailed a risk of incorrect entries and quality deficiencies, in addition to unnecessary work. During our internal

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 30 - 3 FEBRUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination

Cantargia AB today reported an interim update on the first part of the phase Ib clinical study CIRIFOUR. Fifteen cancer patients no longer responding to checkpoint inhibitor therapy received nadunolimab as an add-on to Keytruda® (pembrolizumab) with the primary objective to evaluate safety. The results show a very favorable safety profile, with only one treatment-related grade 3 toxicity identified. As one third of patients are still on therapy, efficacy is planned to be reported in Q2 2022. The next stage of CIRIFOUR will investigate this combination with chemotherapy in non-small cell lung

Swedbank Robur once again appointed Fund Company of the Year

Fondmarknaden.se has for the second year in a row appointed Swedbank Robur “Fund company of the Year”. Earlier this week, Swedbank Robur Technology was also appointed Industry Fund of the Year and Fund of the Year all categories. Swedbank Robur Globalfond was, also for the second year in a row, appointed Global Fund of the Year.Fondmarknaden.se, one of Sweden's largest fund platforms, each year selects winners in 10 different categories, as well as Fund of the Year, Newcomer of the Year and Fund Company of the Year. In the winning motivation for Fund Company of the Year 2021, fondmarknaden.

Humana sharpens quality work - to strengthen operations and prevent serious incidents

The care company Humana AB introduces a new and improved quality index (Humana Quality Index). The groupwide new index incorporates an additional range of relevant measurement areas  to cover further important aspects of how we conduct care. The purpose is to strengthen Humana's operations, prevent serious incidents, and provide added value to our clients.– As one of the largest care providers in the Nordics, we have an obligation to strive towards an increased standard in the care sector. To achieve this, we need to sharpen our quality work further and therefore we invest in more research,

Positive results from the first of four clinical studies to evaluate Brain+’ Starry Night cognitive test for early detection of Alzheimer’s Disease

BRAIN+ A/S (BRAINP) Company Announcement No. 2-2022 Thursday, February 3., 2022, 09:00 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014· Important first step in the clinical validation of Brain+’s gamified version of a proven lab-test to detect early cognitive deficits    · Early detection of Alzheimer’s disease opens up potential for more effective therapeutic interventions · Three other studies on Starry Night will read out later in 2022 A study led by Professor Masud

A vehicle with a future of its own – the electric cargo bike gains ground

myFC Outlook is non-regulatory information, business intelligence, from myFC's communications department. The content reflects industries and segments that are part of or close to the company's sphere of interest. The numbers and data in this text are not to be considered as a forecast for future revenues. The rapid population development of the modern city puts the finger on some problems, such as the infrastructure being overloaded and the air unhealthy when all humans and goods are to be transported. Innovations for sustainable mobility are therefore welcome, such as the electric cargo

Lindex appoints Anna-Karin Dahlberg as Director of Sustainability

Anna-Karin Dahlberg has been appointed Director of Sustainability and new member of Lindex’s management group. Anna-Karin has solid competence as well as long experience of driving a global sustainability agenda and started her new position on 1 February 2022. ‘I am pleased to present Anna-Karin Dahlberg as Lindex’s Director of Sustainability. Anna-Karin has worked close to the management group for many years and with her new role, we will be able to take further steps on our journey as a global fashion company where sustainability is an integrated part of our business. With her

Paulig’s factory in the UK is now carbon neutral

Paulig has reached carbon neutrality in total UK production. Worldwide, the factory, which produces Santa Maria spices and tortilla bread in Milton Keynes in the UK, has become the company’s sixth to achieve carbon neutrality. Vital to achieving this was switching the gas used for baking and frying to renewable gas. As a result, the total emissions from Paulig’s operations are reduced by up to 4%, contributing to the company’s overall objective of lowering them by 80% by 2030 compared to the 2018 baseline. As part of its ambitious sustainability programme, Paulig has obtained the

YIT to build a school in Vääksy in the municipality of Asikkala using the life cycle model

YIT Corporation Investor news 3 February 2022 at 10.00 amYIT and the municipality of Asikkala have signed a contract on the planning and implementation of the Vääksy upper secondary and high school using a life cycle model, the acquisition of which was carried out through a competitive negotiation procedure. The total value of the contract is approximately EUR 28 million. The contract will be entered in the order book of the first quarter of the year. The project includes the design, construction, and maintenance of the new school building for 20 years. The contract also includes an

XMReality appoints new CFO

As of March 1[st], Lotta Ekerbring will take over as Chief Finance Officer (CFO) at XMReality. Lotta will replace the current CFO, Claes Pettersson, who will leave the company for retirement. Lotta will contribute with significant experience in the field and has previous experience as CFO in a high-tech company with subsidiaries in North America.XMReality, a leading supplier of software solutions for Remote Guidance based on Augmented Reality, has appointed Lotta Ekerbring as new Chief Finance Officer. Lotta has worked at XMReality since May 2018 and she will replace Claes Pettersson who

SEB Issues Green Bond of 1 Billion Euro

SEB has raised 1 billion euro through the issuance of a green bond that will be used to finance green loans, in accordance with SEB’s updated framework for green bonds. This is the second green bond that SEB has issued, following the bank’s inaugural green bond in 2017. Interest in the green bond, which was a 5.5-year senior non-preferred bond, was high, with a majority of the investors being European and Nordic financial institutions. “We are very pleased with the high interest from investors in our second green bond. Our new framework is aligned with our customers’ needs and

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2022

Zinzino group revenue increased with a total of 2 %, compared with the previous year.The revenue in January for Zinzino's sales markets remained at the same level as last year and amounted to SEK 102.2 (101.7) million. Faun Pharma's external sales increased by 26% and amounted to SEK 6.7 (5.3) million. Overall, the Group increased revenues by 2% to SEK 108.9 (107.0) million compared with the previous year. Revenues were distributed as follows: Regions,MSEK 22-jan 21-jan ChangeThe Nordics 26.0 30.6 -15%Central Europe 18.4 18.5 -1%East

AnaCardio exercises option to license a program in heart failure from Helsinn

Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has exercised its option to license from Helsinn a program in heart failure, a condition which is associated with poor quality of life, poor prognosis and which remains a major unmet medical need. Under the

Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions

VAMDRUP, Denmark, February 3rd, 2022 – Impilo, together with SHS, have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners.Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance market. Following an initial period of product refinement and establishment of go-to-market activities, Lowenco has over the past three years gained significant commercial traction and is

CS MEDICA A/S signs partnership with Ampilio in preparation of Amazon expansion

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the Company has signed a partnership with Ampilio AB (“Ampilio”), a subsidiary of SpectrumOne. Ampilio will assist CS MEDICA as a business strategist, growth specialist as CS MEDICA prepares to execute global expansion on Amazon. The agreement comprises that Ampilio will run sales activities and develop a digital strategy and assist CS MEDICA in the global launch on Amazon. The partnership is a running agreement with a fixed annual fee of 270 000 SEK.CS MEDICA is currently working on expanding the Company’s marketing

Ampilio, a subsidiary of SpectrumOne, signs with Danish company CS MEDICA A/S to execute on expansion

Ampilio, a subsidiary of SpectrumOne, partners up with stock exchange listed medical company CS MEDICA as digital business strategist, growth specialists and executor of their  global expansion on Amazon. Ampilio will run all sales, digital strategy, and expansion on Amazon with a global launch. The deal is valued at 270 000 SEK annually with a continued agreement until either partner decides otherwise.  CS MEDICA is a Danish leading OTC Medical Device Provider active in medical technology. The company specializes in the development of medical devices. The portfolio includes products

BioStock: Abliva is ready for a pivotal year

During 2021 Lund-based Abliva laid the ground for an eventful 2022 as it achieved significant advancements with its two candidates within the primary mitochondrial disease space. Lead candidate KL1333 is to enter a registrational phase II/III study during 2022, whilst the second candidate, NV354, has been given the go-ahead to proceed to clinical studies. During the last days of 2021 the company also announced a directed issue of convertible bonds in order to further advance KL1333 and provide bridge financing.Read the article and interview with Abliva's CEO Ellen Donnelly at biostock.se (

Martin du Hane har utsetts till permanent VD och Koncernchef för Moment Group AB

Styrelsen har utsett Martin du Hane till permanent VD och Koncernchef för Moment Group AB. Martin du Hane tillträdde den 22 mars 2021 befattningen som tillförordnad VD/Koncernchef och den rollen har med detta övergått till att vara permanent.- Uppdraget för den som ytterst ska leda Moment Group framåt är tydligt – att återställa lönsamheten efter denna tuffa period med stängda verksamheter och samtidigt bygga plattformen för tillväxt. Vi har nu gjort ett grundligt arbete i rekryteringsprocessen för att finna rätt VD för koncernen och vi i styrelsen är mycket glada att Martin tackade ja till

Additional DrugLog order from B. Braun Spain

B. Braun Spain has placed another order for a complete DrugLog® system for installation at Hospital General Universitari de Castelló. The order is a result of the collaboration between B. Braun Spain and Pharmacolog.The collaboration between B. Braun Spain has been ongoing for a number of years where Pharmacolog's products DrugLog and PrepLog have been adapted to fit in with B. Braun's solutions for safe handling of critical drugs. The launch was delayed due to the pandemic but began in 2021. Today's order concerns installation at Hospital General Universitari de Castelló in Castello de la

HKScan plans to streamline its operating model

HKScan Corporation, Press Release, 3 February 2022, at 9:30 am EETHKScan plans to streamline its operating model  HKScan is planning to streamline the operating model between the Group functions and Business Units. In the future, HKScan’s Group functions are planned to focus more closely on the Group’s key strategic development projects and leadership as well as activities that ensure good corporate governance of a listed company. HKScan will begin statutory negotiations simultaneously in the Group functions and Business Unit Finland. HKScan renewed its Group-wide operating model at

SEB’s The Green Bond: Energy Investments to Surge in 2022

The cost advantage of renewable energy over fossil alternatives continues to widen, and incoming data is starting to confirm a surge in energy investment that will also accelerate the transition for energy-using sectors. SEB’s latest The Green Bond report explores this development, and how 2022 is likely to be the first year when total transition investment exceeds USD 1 trillion. In this issue of The Green Bond, titled Biodiversity in the Spotlight, we also take a deep dive into the topic of biodiversity – particularly looking at how businesses and investors are now moving beyond climate-

Year End Report 2021

Press release, Stockholm, Sweden, 3 February 2022 Good growth despite challenges Fourth quarter 2021 · Net sales increased during the fourth quarter by 23,2% to 83,5 MSEK (67,8). Currency translations had a positive effect of 1,4 MSEK on net sales. · Adjusted EBITDA decreased during the fourth quarter by 7,1% to 5,1 MSEK (5,5), corresponding to an adjusted EBITDA margin by 6,1 % (8,1) · Operating profit/loss was -1,7 MSEK (-1,0) which correspond to operating margin of -2,0% (-1,5) · Profit for the quarter was -4,3 MSEK (-2,6) · Result per share was -0,29 (-0,18) SEK[1]

Year-end report Rejlers AB January – December 2021

October – December   · Net sales increased by 32.4% to SEK 835.9 million (631.2) · Organic sales growth excluding exchange rate fluctuations increased to 22.1% (-5.1) · Adjusted EBITA, excluding restructuring costs, increased by 87% to SEK 66.5 million (35.6) and the adjusted EBITA margin increased to 8.0% (5.6). · Restructuring costs amounted to SEK 18.2 million (0) · EBITA increased to SEK 48.3 million (35.6) and the EBITA margin increased to 5.8% (5.6) · Operating profit (EBIT) increased to SEK 37.4 million (28.0), impacted by acquisition costs of SEK 2.5 million (2.7)

There are no items matching the current filter
There are no more items matching the current filter
Back to top